Advertisement

Status of Controlled Clinical Trials in Peripheral Vessel Atherosclerosis

  • Stanley Azen
  • David H. Blankenhorn
  • Sharon Nessim

Abstract

There are two general strategies to test the efficacy of drugs which may cause atherosclerosis regression in man. The first is to study drug effects on atherosclerosis-related morbidity or mortality, a strategy which has been accepted for many years. For example, the Coronary Drug Project1 studied the effects of six drugs in men aged 30 to 64 years who had recovered from one or more episodes of myocardial infarction (MI). Fifty-three clinics recruited 8,341 patients who were randomly assigned to one of six treatment groups. Three study groups (conjugated estrogens, 2.5 mg/day; conjugated estrogens, 5.0 mg/day; and dextrothyroxine sodium, 6.0 mg/day) were discontinued before the scheduled conclusion of the project, whereas patients in the remaining groups (Clofibrate, 1.8 g/day; niacin, 3.0 g/day; and lactose placebo 3.8 g/day) were followed to the end of the study. The results of that study indicated that there was no evidence of significant efficacy of Clofibrate or of niacin with regard to total mortality or cause-specific mortality. Five-year mortality rates were 20.0% for Clofibrate, 21.2% for niacin, and 20.9% for the placebo.

Keywords

Drug Group Coronary Heart Disease Mortality Blood Lipid Level Multiple Risk Factor Intervention Trial Atherosclerosis Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The Coronary Drug Project Research Group, Clofibrate and niacin in coronary heart disease, JAMA 231: 360 (1975).CrossRefGoogle Scholar
  2. 2.
    Multiple Risk Factor Intervention Trial Research Group, Multiple risk factor intervention trial. Risk factor changes and mortality results, JAMA 248: 1465 (1982).CrossRefGoogle Scholar
  3. 3.
    M. F. Oliver, J. A. Heady, J. N. Morris, et al., A cooperative trial in the primary prevention of ischemic heart disease using Clofibrate. Report from the Committee of Principal Investigators, Br. Heart J. 40: 1069 (1978).CrossRefGoogle Scholar
  4. 4.
    D. H. Blankenhorn, Review of clinical studies: discussion, in: “Clinical Diagnosis of Atherosclerosis. Quantitative Methods of Evaluation,” M. G. Bond, W. Insull Jr., S. Glagov, A. B. Chandler, and J. D. Cornhill, eds., Springer-Verlag, New York (1982).Google Scholar
  5. 5.
    R. Barndt Jr., D. H. Blankenhorn, D. W. Crawford, and S. H. Brooks, Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann. Intern. Med. 86: 139 (1977).CrossRefGoogle Scholar
  6. 6.
    S. H. Brooks, D. H. Blankenhorn, H. P. Chin, M. E. Sanmarco, P. K. Hanashiro, R. H. Selzer, and R. H. Selvester, Design of human atherosclerosis studies by serial angiography. J. Chronic Dis. 33: 347 (1980).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Stanley Azen
    • 1
  • David H. Blankenhorn
    • 1
  • Sharon Nessim
    • 1
  1. 1.Departments of Preventive Medicine and Medicine, School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations